LondonPharma is a privately owned UK biopharmaceutical research and development company with a successful track record of product development; repurposing existing drugs for sublingual delivery.
The company has product development programmes underway in various indications including cancer (LON002 in Phase lb/lla clinical trials), Lyme disease, blood-fluke, erectile dysfunction, pain, addiction and nausea using its repurposing expertise for sublingual delivery. The company’s strategy is to take its product development programmes through to proof-of-efficacy in man and then license those programmes to corporate partners.
Founded in 2007, LondonPharma initially demonstrated its expertise in repurposing existing molecules through the sublingual delivery of a treatment for severe malaria in children. A separate joint venture company has since been formed with a partner to commercialise the use of the drug in this indication.
LondonPharma is based in two main locations; its corporate head office in Oxford, UK and its laboratories at the Innovation Centre, Norwich Research Park, Norwich, UK. The company’s business model is semi-virtual combining the in-house development of the core delivery technology and science with the out-sourcing of specialist biology, toxicology, regulatory and clinical development programmes.
Updated: 13/7/14Print this page